• +1 (732) 369 9777
  • +1 (609) 857 6083
  • enquiry@dimensionmarketresearch.com

/images/logo.png
  • About Us
  • Insight
    Trending Reports Latest Reports
  • Industries
    Aerospace & Defence
    Agriculture & Horticulture
    Automotive
    BFSI & Education
    Chemical & Material
    Consumer Goods
    Electrical & Semiconductor
    ICT & TMT
    Energy & Power
    Food & Beverages
    Industry Automation & Equipment
    Manufacturing & Construction
    Medical Devices & Healthcare IT
    Metals & Minerals
    Packaging & Logistics
    Pharmaceuticals & Healthcare
    Sports & Fitness
  • News And Media
  • Contact us
/images/logo.png
  • home
  • Chemical & Material
  • Biologics Market

Biologics Market By Source (Microbial, Mammalian, and Others), By Product, By Disease, By Manufacturing - Global Industry Outlook, Key Companies (Amgen Inc, AbbVie Inc, Pfizer Inc, and Others), Trends and Forecast 2023-2032

Published on : November-2023  Report Code : RC-545  Pages Count : 251  Report Format : PDF
Overview Table of Content Download Report's Excerpt Request Free Sample

Market Overview

The Global Biologics Market is expected to reach a value of USD 538.2 billion in 2023, and it is further anticipated to reach a market value of USD 1,342.7 billion by 2032 at a CAGR of 10.7%.

Biologics, also known as biological medications, are disease-modifying drugs made from living organisms or their components. They contain blood products, vaccines, tissues, & more derived from different sources like animals, humans, & plants. These substances influence essential proteins, modify hormones & cells, and can either boost or suppress the immune system, ultimately impacting natural biological processes.

Biologics Market Growth Analysis
Biologics are complex, large-molecule drugs derived from living cells, tissues, or organisms, often targeting specific diseases with high efficacy and fewer side effects compared to traditional drugs. They're primarily used in treating chronic and life-threatening conditions like cancer, autoimmune disorders, and rare diseases. 

The biologics market is growing rapidly due to increased demand for personalized medicine and advancements in biotechnology. Important conferences include the BIO International Convention, BioProcess International Conference, and World Biosimilar Congress. 

Recent industry surveys reveal a strong market focus on biosimilars, cell, and gene therapies, with significant investment in R&D and manufacturing capacity. 

According to Allergy, Asthma & Clinical Immunology, in a study of 5,997 patients (58% male, mean age 48.1), 10.7% (642) used biologics. Asthma was more common in biologic users (89.1%) than non-users (35%; P<0.001). Biologic users had fewer diagnostic (but more drug-related) services. 

Among 11.6% of sinus surgery patients using biologics, 56.1% started treatment before surgery, and 12.5% began ≤30 days post-surgery. Oral corticosteroid (OCS) use was higher in biologic users (68.8% vs 42.5%; P<0.001). Asthma raised biologic use odds by 5.46 times; age <65, prior OCS/doxycycline, and comorbidities also increased use.

Recent news highlights include regulatory advancements for biosimilars, partnerships for novel cell and gene therapies, and innovations in manufacturing to reduce costs and improve accessibility.

Market Dynamic

According to the World Health Organization (WHO), about 41 million people lose their lives to chronic diseases annually. The most common among these is cardiovascular disease, causing about 17.9 million lives per year, followed by cancer, diabetes, & respiratory disorders. Together, these four categories are responsible for a higher 80% of all chronic disease-related deaths. 

The prevalence of chronic diseases has driven advancements in advanced diagnostics & treatments. Biologics, which are commonly engineered medicines targeting the immune system to fight inflammation, play a major role in addressing these health challenges. The growth of the biologics market is further influenced by growing healthcare expenditures & government initiatives focused on enhancing healthcare infrastructure.

However, many challenges are there in the biologics market, like the high costs associated with drug development & distribution create obstacles to growth. Also, limited healthcare infrastructure in developing economies, less skilled professionals, & a lack of awareness about biologics in research facilities may restrain and impede market growth. Moreover, the sensitivity of biologics to heat & light necessitates precise refrigeration, which is not consistently available worldwide, further hindering the market's growth.

Research Scope and Analysis

By Source

The global biologics market in terms of source is categorized into microbial, mammalian, and others. In 2023, the microbial source category takes a leading position within the biologics industry, holding a substantial share, which is primarily because a majority of the biologics currently approved have been created & produced using microbial expression systems. In addition, products like platelet-derived growth factor, granulocyte-macrophage colony-stimulating factor, recombinant insulin, & recombinant interferons are all manufactured in microbial expression systems.

Further, the mammalian expression systems segment is anticipated to witness major growth in the forecasted period. These systems are predominantly used for developing recombinant proteins & viral-vector-based vaccines. The most commonly used mammalian cell lines in this context are CHO & HEK, which are driven by their effectiveness in producing these advanced biological products, marking an encouraging avenue for future growth in the biologics market.

By Product

Regarding the product, the monoclonal antibodies (MABs) category takes a substantial share in 2023, particularly because these drugs find broad application across several therapeutic areas. MABs offer the advantage of precisely targeting diseased cells while saving healthy ones, making them a popular choice in biological therapies, as they have emerged as the prominent category among approved biologic drugs to date.

Also, the antisense and RNAi therapeutics segment is expected to have significant growth in the coming years. These biological products enable accurate and effective gene silencing, resulting in the development and approval of numerous gene-silencing drugs for genetic diseases. This expansion is driven by the potential to address specific genetic conditions, making it a major segment in driving the biologics market's future.

Biologics Market Product Analysis

By Disease

The oncology category in the diseases category stands as the driving factor in the biologics industry, holding a significant share in 2023. This is primarily due to the alarming prevalence of cancer, where approximately 2 million new cases and over 600,000 cancer-related deaths were reported in the U.S. in 2022 as per the American Cancer Society. Further, the introduction of biologic treatments, mainly monoclonal antibodies & immunotherapy, has markedly enhanced cancer care, increasing survival rates & lowering the side effects. In addition, biological drugs have left a positive mark on breast cancer treatment, as seen with the successful use of Herceptin.

Moreover, the hematological disorder category is anticipated to experience the most rapid growth in the forecast period, which is driven by the approval of gene therapy for rare blood disorders like hemophilia, which is a significant factor driving the market expansion.

By Manufacturing

The in-house manufacturing segment holds the dominant share of the market in 2023, as manufacturing biological drugs is more complex compared to small molecules, including live micro-organism cultures & strict regulatory compliance. In-house manufacturing gives the advantage of direct control, enabling better day-to-day monitoring of biological drug production.

In addition, the outsourcing segment is expected to grow at a high rate in the coming years, as numerous Contract Development & Manufacturing Organizations (CDMOs) like Lonza, Wuxi Biologics, & Samsung Biologics have established state-of-the-art biologic manufacturing facilities. Collaborating with these CDMOs gives organizations access to manufacturing experts, allowing successful downstream process development & the integration of new technologies. The market's growth is highly influenced by the growth in the number of CDMOs & their expansion in production capacity.

The Biologics Market Report is segmented on the basis of the following

By Source

  • Microbial
  • Mammalian
  • Others

By Product

  • Monoclonal Antibodies
  • Antisense & RNAi Therapeutics
  • Vaccines
  • Recombinant Proteins
  • Others

By Disease

  • Oncology
  • Infectious Diseases
  • Cardiovascular Disorders
  • Immunological Disorders
  • Hematological Disorders
  • Others

By Manufacturing

  • In-house
  • Outsourced

Regional Analysis

North America leads the global biologics market with the largest share of 45.7% in 2023 in terms of market revenue due to various factors, which include a high prevalence of chronic diseases, the presence of key biopharmaceutical companies, favorable reimbursement policies, & high investments in R&D. The growth in the use of biologic prescriptions & investments in targeted drug development also contribute to market growth. In addition, the approval of innovative biological drugs like antisense & RNAi therapeutics, and gene therapy, is expected to drive further expansion.

Also, the Asia Pacific region is set to experience significant growth during the forecasted period. The growth in the number of diseases like diabetes, cancer, and heart conditions, along with a rise in the elderly population, has led to a rise in demand for biologics. Market leaders are investing in advanced biologic products to meet this need, and the adoption of biosimilars is playing an important role in enhancing the accessibility & affordability of biologic treatments, further fueling market growth in the region.

Biologics Market Regional Analysis

By Region

North America
  • The U.S.
  • Canada
Europe
  • Germany
  • The U.K.
  • France
  • Italy
  • Russia
  • Spain
  • Benelux
  • Nordic
  • Rest of Europe
Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • ANZ
  • ASEAN
  • Rest of Asia-Pacific
Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of Latin America
Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Israel
  • Egypt
  • Rest of MEA

Competitive Landscape

The biologics market has a decent level of competition with many key players, who are using strategies like launching new products, mergers, acquiring other companies, & forming partnerships to enhance their positions in the market. They also invested a lot of money in R&D biologics as they are quite expensive to make.

Like, in February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson got the green light from the US Food and Drug Administration (FDA) for a biologic medication called CARVYKTI, which is developed to assist adults with a challenging form of multiple myeloma, known as RRMM (relapsed or refractory multiple myeloma), when they've already tried four or more different treatments, including specific types of drugs like immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibodies.

Some of the prominent players in the global Biologics Market are:
  • Amgen Inc
  • Sanofi
  • AbbVie Inc.
  • Johnson & Johnson
  • Samsung Biologics
  • Merck & Co.
  • Pfizer Inc.
  • Novartis AG
  • Bayer AG
  • AstraZeneca PLC
  • Other Key Players

COVID-19 Pandemic & Recession: Impact on the Global Biologics Market

The COVID-19 pandemic & the following economic recession had significant effects on the global biologics market. The pandemic accelerated the research & development of biological treatments & vaccines, leading to growing demand & innovation in the industry. However economic challenges & disruptions in healthcare systems strained access to healthcare & financial resources, affecting the cost-effectiveness of biologics. 

The market experienced changes in supply chains & distribution, and some patients experienced delays in treatment. Despite these challenges, the biologics market remained volatile, adapting to the changing landscape, & its long-term growth prospects remain promising as the world continues to address the ongoing pandemic & its economic repercussions.

Report Details

Report Characteristics
Market Size (2023) USD 538.2 Bn
Forecast Value (2032) USD 1,342.7 Bn
CAGR (2023-2032) 10.7%
Historical Data 2017 - 2022
Forecast Data 2023 - 2032
Base Year 2022
Estimate Year 2023
Report Coverage Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc.
Segments Covered By Source (Microbial, Mammalian, and Others) By Product, Monoclonal Antibodies, Antisense & RNAi Therapeutics, Vaccines, Recombinant Proteins, and Others), By Disease (Oncology, Infectious Diseases, Cardiovascular Disorders, Immunological Disorders, Hematological Disorders, and Others), By Manufacturing (In-house and Outsourced)
Regional Coverage North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
Prominent Players Amgen Inc., Sanofi, AbbVie Inc., Johnson & Johnson, Samsung Biologics, Merck & Co., Pfizer Inc., Novartis AG, Bayer AG, AstraZeneca PLC, and Other Key Players
Purchase Options We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users), and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days and 5 analysts working days respectively.

 

Frequently Asked Questions

  • How big is the Global Biologics Market?

    The Global Biologics Market is estimated to reach USD 538.2 billion in 2023, which is further expected to reach USD 1,342.7 billion by 2032.

  • Which region accounted for the largest Global Biologics Market?

    North America dominates the Global Biologics Market with a share of 45.7% in 2023.

  • Who are the key players in the Global Biologics Market?

    Some of the major key players in the Global Biologics Market are Amgen Inc., AbbVie Inc., Pfizer Inc., and many others.

  • What is the growth rate in the Global Biologics Market?

    The market is growing at a CAGR of 10.7 percent over the forecasted period.

  • Contents

      1.Introduction
        1.1.Objectives of the Study
        1.2.Market Scope
        1.3.Market Definition and Scope
      2.Biologics Market Market Overview
        2.1.Global Biologics Market Market Overview by Type
        2.2.Global Biologics Market Market Overview by Application
      3.Biologics Market Market Dynamics, Opportunity, Regulations, and Trends Analysis
        3.1.Market Dynamics
          3.1.1.Biologics Market Market Drivers
          3.1.2.Biologics Market Market Opportunities
          3.1.3.Biologics Market Market Restraints
          3.1.4.Biologics Market Market Challenges
        3.2.Emerging Trend/Technology
        3.3.PESTLE Analysis
        3.4.PORTER'S Five Forces Analysis
        3.5.Technology Roadmap
        3.6.Opportunity Map Analysis
        3.7.Case Studies
        3.8.Opportunity Orbits
        3.9.Pricing Analysis
        3.10.Ecosystem Analysis
        3.11.Supply/Value Chain Analysis
        3.12.Covid-19 & Recession Impact Analysis
        3.13.Product/Brand Comparison
      4.Global Biologics Market Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by By Source, 2017-2032
        4.1.Global Biologics Market Market Analysis by By Source: Introduction
        4.2.Market Size and Forecast by Region
        4.3.Microbial
        4.4.Mammalian
        4.5.Others
      5.Global Biologics Market Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by By Product, 2017-2032
        5.1.Global Biologics Market Market Analysis by By Product: Introduction
        5.2.Market Size and Forecast by Region
        5.3.Monoclonal Antibodies
        5.4.Antisense & RNAi Therapeutics
        5.5.Vaccines
        5.6.Recombinant Proteins
        5.7.Others
      6.Global Biologics Market Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by By Disease, 2017-2032
        6.1.Global Biologics Market Market Analysis by By Disease: Introduction
        6.2.Market Size and Forecast by Region
        6.3.Oncology
        6.4.Infectious Diseases
        6.5.Cardiovascular Disorders
        6.6.Immunological Disorders
        6.7.Hematological Disorders
        6.8.Others
      7.Global Biologics Market Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by By Manufacturing, 2017-2032
        7.1.Global Biologics Market Market Analysis by By Manufacturing: Introduction
        7.2.Market Size and Forecast by Region
        7.3.In-house
        7.4.Outsourced
      10.Global Biologics Market Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2017-2032
        10.1.North America
          10.1.1.North America Biologics Market Market: Regional Analysis, 2017-2032
            10.1.1.1.The US
            10.1.1.2.Canada
        10.2.1.Europe
          10.2.1.Europe Biologics Market Market: Regional Trend Analysis
            10.2.1.1.Germany
            10.2.1.2.France
            10.2.1.3.UK
            10.2.1.4.Russia
            10.2.1.5.Italy
            10.2.1.6.Spain
            10.2.1.7.Nordic
            10.2.1.8.Benelux
            10.2.1.9.Rest of Europe
        10.3.Asia-Pacific
          10.3.1.Asia-Pacific Biologics Market Market: Regional Analysis, 2017-2032
            10.3.1.1.China
            10.3.1.2.Japan
            10.3.1.3.South Korea
            10.3.1.4.India
            10.3.1.5.ANZ
            10.3.1.6.ASEAN
            10.3.1.7.Rest of Asia-Pacifc
        10.4.Latin America
          10.4.1.Latin America Biologics Market Market: Regional Analysis, 2017-2032
            10.4.1.1.Brazil
            10.4.1.2.Mexico
            10.4.1.3.Argentina
            10.4.1.4.Colombia
            10.4.1.5.Rest of Latin America
        10.5.Middle East and Africa
          10.5.1.Middle East and Africa Biologics Market Market: Regional Analysis, 2017-2032
            10.5.1.1.Saudi Arabia
            10.5.1.2.UAE
            10.5.1.3.South Africa
            10.5.1.4.Israel
            10.5.1.5.Egypt
            10.5.1.6.Turkey
            10.5.1.7.Rest of MEA
      11.Global Biologics Market Market Company Evaluation Matrix, Competitive Landscape, Market Share Analysis, and Company Profiles
        11.1.Market Share Analysis
        11.2.Company Profiles
        11.3.Amgen Inc
          11.3.1.Company Overview
          11.3.2.Financial Highlights
          11.3.3.Product Portfolio
          11.3.4.SWOT Analysis
          11.3.5.Key Strategies and Developments
        11.4.Sanofi
          11.4.1.Company Overview
          11.4.2.Financial Highlights
          11.4.3.Product Portfolio
          11.4.4.SWOT Analysis
          11.4.5.Key Strategies and Developments
        11.5.AbbVie Inc.
          11.5.1.Company Overview
          11.5.2.Financial Highlights
          11.5.3.Product Portfolio
          11.5.4.SWOT Analysis
          11.5.5.Key Strategies and Developments
        11.6.Johnson & Johnson
          11.6.1.Company Overview
          11.6.2.Financial Highlights
          11.6.3.Product Portfolio
          11.6.4.SWOT Analysis
          11.6.5.Key Strategies and Developments
        11.7.Samsung Biologics
          11.7.1.Company Overview
          11.7.2.Financial Highlights
          11.7.3.Product Portfolio
          11.7.4.SWOT Analysis
          11.7.5.Key Strategies and Developments
        11.8.Merck & Co.
          11.8.1.Company Overview
          11.8.2.Financial Highlights
          11.8.3.Product Portfolio
          11.8.4.SWOT Analysis
          11.8.5.Key Strategies and Developments
        11.9.Pfizer Inc.
          11.9.1.Company Overview
          11.9.2.Financial Highlights
          11.9.3.Product Portfolio
          11.9.4.SWOT Analysis
          11.9.5.Key Strategies and Developments
        11.10.Novartis AG
          11.10.1.Company Overview
          11.10.2.Financial Highlights
          11.10.3.Product Portfolio
          11.10.4.SWOT Analysis
          11.10.5.Key Strategies and Developments
        11.11.Bayer AG
          11.11.1.Company Overview
          11.11.2.Financial Highlights
          11.11.3.Product Portfolio
          11.11.4.SWOT Analysis
          11.11.5.Key Strategies and Developments
        11.12.AstraZeneca PLC
          11.12.1.Company Overview
          11.12.2.Financial Highlights
          11.12.3.Product Portfolio
          11.12.4.SWOT Analysis
          11.12.5.Key Strategies and Developments
        11.13.Other Key Players
          11.13.1.Company Overview
          11.13.2.Financial Highlights
          11.13.3.Product Portfolio
          11.13.4.SWOT Analysis
          11.13.5.Key Strategies and Developments
      12.Assumptions and Acronyms
      13.Research Methodology
      14.Contact
    If your country is missing in the list, we apologize that we still do not serve in your country.

    Your personal details are safe and secured with us.

    If your country is missing in the list, we apologize that we still do not serve in your country.

    Your personal details are safe and secured with us.

    Select License Type


    • RC-545

    • November-2023
      • ★★★★★
        ★★★★★
      • 62
    • $3190
    • $4590
    • $5690
    Download Free Brochure Customization Request Buy Country Level Reports Request Discount
    Chat on WhatsApp

    Get in Touch with Us

    • US : +1 732 369 9777
    • India : +91 88267 74855

    Related Report

    • 1-Decene Market
    • Narrow Range Ethoxylates Market
    • Ethylene Propylene Diene Monomer (EPDM) Market
    • Medical Fluoropolymers Market
    • Specialty Fuel Additives Market
    • Bio-Acetic Acid Market
    • Plastic Market
    • Carbon Dioxide Market
    • Intermediate Bulk Container Liner Market
    • Plastic Compounding Market
    Secured Payment Options
      /images/payment.png
    Legal
    • Privacy Policy
    • Refund Policy
    • Frequently Asked Questions
    • Terms and Conditions
    Explore Company
    • About Us
    • Contact Us
    • Trending Reports
    • Latest Reports
    • All Industries
    • How to Order
    Contact Detail
    • 957 Route 33, Suite 12 #308
            Hamilton Square, NJ-08690 USA
    • +1 (123) 456 4562 (International)
    • +1 (609) 857 6083 (International)
    • +91 882 677 4855 (Asia)
    • sales@dimensionmarketresearch.com
    Copyright Market Research. ©2025 All rights reserved